Related Experiment Video
Updated: May 7, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Effect of del Nido cardioplegia in patients with reduced left ventricular ejection fraction: A meta-analysis
Yoshiyuki Yamashita1,2, Massimo Baudo2, Dimitrios E Magouliotis2
1Department of Cardiothoracic Surgery, Lankenau Heart Institute, Wynnewood, PA, USA.
Insights
Del Nido cardioplegia is safe and effective for adult cardiac surgery patients with reduced ejection fraction. It shows comparable mortality and morbidity to conventional methods, with potential benefits for heart function.
Area of Science:
- Cardiovascular Surgery
- Cardioplegia Solutions
- Myocardial Protection
Background:
- Limited research exists on del Nido cardioplegia in adults with reduced left ventricular ejection fraction (LVEF).
- Assessing early outcomes in this specific patient cohort is crucial for clinical practice.
Purpose of the Study:
- To evaluate the safety and efficacy of del Nido cardioplegia in adult patients with reduced LVEF (≤50%).
- To compare early surgical outcomes between del Nido and conventional cardioplegia in this population.
Main Methods:
- A meta-analysis was conducted using studies from PubMed, Scopus, and Cochrane Central Register up to August 2024.
- Included adult patients with LVEF ≤50% undergoing cardiac surgery, comparing del Nido to other cardioplegia solutions.
- Primary endpoint: early mortality. Secondary endpoints: morbidities, aortic cross-clamp time, and postoperative LVEF.
Main Results:
- Seven studies (1160 patients) were analyzed, with conventional blood cardioplegia as the control.
- No significant difference in early mortality (OR 0.94; p=.822) or major morbidities (stroke, renal failure, atrial fibrillation) was observed.
- Postoperative LVEF was significantly higher in the del Nido group (SMD 0.52; p=.034), suggesting myocardial protection.
Conclusions:
- Del Nido cardioplegia demonstrates comparable safety and efficacy to conventional solutions in adult cardiac surgery patients with reduced LVEF.
- The findings suggest del Nido cardioplegia may offer protective benefits to myocardial function in this vulnerable group.
Abstract:
PurposeResearch on the safety and efficacy of del Nido cardioplegia in adult patients with reduced left ventricular ejection fraction (LVEF) is limited. We evaluated the effect of del Nido cardioplegia on early outcomes of cardiac surgery in this cohort.MethodsPubMed, Scopus, and the Cochrane Central Register of Controlled Trials were searched through August 2024 to conduct a meta-analysis comparing del Nido to other cardioplegia in adult patients with reduced LVEF (≤50%). Primary endpoint was early mortality, and secondary endpoints included morbidities, aortic cross-clamp time and postoperative LVEF before discharge. A random-effect model was used to estimate the pooled effect size.ResultsSeven studies met our eligibility criteria, including three propensity score-matched studies with a total of 1160 patients. Conventional blood cardioplegia was used exclusively as a control solution in the included studies. The incidence of early mortality was similar between the del Nido and control groups, with a pooled odds ratio of 0.94 [95% confidence interval: 0.52; 1.71] (p = .822). Postoperative stroke (p = .680), renal failure (p = .832), atrial fibrillation (p = .412), and aortic cross-clamp time (p = .153) were also comparable between the two groups. Postoperative LVEF was significantly higher in the del Nido group compared to the control group, with a standardized mean difference of 0.52 [95% confidence interval: 0.07; 0.96] (p = .034).ConclusionsIn adult patients with reduced LVEF undergoing cardiac surgery, del Nido cardioplegia provides comparable mortality and morbidity rates compared to conventional blood cardioplegic solutions, with the potential to offer protective effects on myocardial function.
Related Concept Videos
Heart Failure II: Pathophysiology
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VI: Nursing Management

